Novartis investors watch 3 drug trials seen worth over $10 billion

Analysts say late-stage readouts due in the second half are critical as patent expiries for Cosentyx and Kisqali approach and Entresto already faces generic pressure.

OP

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.